Literature DB >> 21357657

Nonsteroidal antiinflammatory drug use and lower urinary tract symptoms: results from the Boston area community health survey.

Margaret A Gates1, Susan A Hall, Gretchen R Chiu, Varant Kupelian, Mary P Fitzgerald, Carol L Link, John B McKinlay.   

Abstract

There is evidence for a role of inflammation in the etiology of lower urinary tract symptoms (LUTS), raising the possibility that use of nonsteroidal antiinflammatory drugs (NSAIDs) may inhibit the development or progression of LUTS. The authors examined the association between use of prescription and over-the-counter NSAIDs and LUTS among 1,974 men and 2,661 women in the Boston Area Community Health Survey (2002-2005). Multivariable-adjusted logistic regression was used to estimate odds ratios and 95% confidence intervals for LUTS, voiding symptoms, storage symptoms, and nocturia. There was no clear association between use of prescription or over-the-counter NSAIDs (compared with no NSAID use) and overall LUTS, voiding symptoms, or nocturia in men or women. However, over-the-counter NSAID use was positively associated with storage symptoms in women (odds ratio = 1.37, 95% confidence interval: 1.03, 1.83), and there was a positive association between over-the-counter NSAID use and overall LUTS among women with a history of arthritis (odds ratio = 2.09, 95% confidence interval: 1.20, 3.64). These results do not provide strong support for an association between NSAIDs and LUTS. However, the associations between over-the-counter NSAID use and certain urologic symptoms, particularly among women with arthritis, and the potential mechanisms involved should be evaluated in future studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21357657      PMCID: PMC3121220          DOI: 10.1093/aje/kwq473

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  39 in total

1.  Acute urinary retention associated with the use of cyclooxygenase-2 inhibitors.

Authors:  Jennifer Gruenenfelder; Edward J McGuire; Gary J Faerber
Journal:  J Urol       Date:  2002-09       Impact factor: 7.450

2.  A revised CES-D measure of depressive symptoms and a DSM-based measure of major depressive episodes in the elderly.

Authors:  C L Turvey; R B Wallace; R Herzog
Journal:  Int Psychogeriatr       Date:  1999-06       Impact factor: 3.878

3.  A comparison between bromocriptine and indomethacin in the treatment of detrusor instability.

Authors:  L D Cardozo; S L Stanton
Journal:  J Urol       Date:  1980-03       Impact factor: 7.450

4.  Manual for scoring socioeconomic status for research on health behavior.

Authors:  L W Green
Journal:  Public Health Rep       Date:  1970-09       Impact factor: 2.792

5.  Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).

Authors:  Franco Di Silverio; Cesare Bosman; Monti Salvatori; Luca Albanesi; Laura Proietti Pannunzi; Mauro Ciccariello; Antonio Cardi; Gianfilippo Salvatori; Alessandro Sciarra
Journal:  Eur Urol       Date:  2005-01       Impact factor: 20.096

6.  Obstruction stimulates COX-2 expression in bladder smooth muscle cells via increased mechanical stretch.

Authors:  J M Park; T Yang; L J Arend; J B Schnermann; C A Peters; M R Freeman; J P Briggs
Journal:  Am J Physiol       Date:  1999-01

7.  Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium.

Authors:  Wanzhong Wang; Anders Bergh; Jan-Erik Damber
Journal:  Prostate       Date:  2004-09-15       Impact factor: 4.104

8.  Risk behaviours and benign prostatic hyperplasia.

Authors:  D Kang; G L Andriole; R C Van De Vooren; D Crawford; D Chia; D A Urban; D Reding; W-Y Huang; R B Hayes
Journal:  BJU Int       Date:  2004-06       Impact factor: 5.588

9.  Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis.

Authors:  Grégoire Robert; Aurélien Descazeaud; Nathalie Nicolaïew; Stéphane Terry; Nanor Sirab; Francis Vacherot; Pascale Maillé; Yves Allory; Alexandre de la Taille
Journal:  Prostate       Date:  2009-12-01       Impact factor: 4.104

10.  Effectiveness of a nonsteroidal anti-inflammatory drug for nocturia on patients with benign prostatic hyperplasia: a prospective non-randomized study of loxoprofen sodium 60 mg once daily before sleeping.

Authors:  Tohru Araki; Teruhiko Yokoyama; Hiromi Kumon
Journal:  Acta Med Okayama       Date:  2004-02       Impact factor: 0.892

View more
  4 in total

1.  Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey.

Authors:  Varant Kupelian; Raymond C Rosen; Claus G Roehrborn; Pradeep Tyagi; Michael B Chancellor; John B McKinlay
Journal:  BJU Int       Date:  2011-12-16       Impact factor: 5.588

2.  Characteristics of urinary retention in female inpatients managed with medical treatments.

Authors:  Chang Yong Lee; Chul Sung Kim; Won Jin Cho
Journal:  Korean J Urol       Date:  2015-11-26

3.  The role of prescription drugs in female overactive bladder syndrome-A population-wide cohort study.

Authors:  Wolfgang Umek; Andreas Gleiss; Barbara Bodner-Adler; Berthold Reichardt; Christoph Rinner; Georg Heinze
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-12-05       Impact factor: 2.890

4.  Prevalence of commonly prescribed medications potentially contributing to urinary symptoms in a cohort of older patients seeking care for incontinence.

Authors:  Mandavi Kashyap; Le Mai Tu; Cara Tannenbaum
Journal:  BMC Geriatr       Date:  2013-06-10       Impact factor: 3.921

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.